CSIMarket Company Name, Ticker, Customers, else..
 
Context Therapeutics Inc   (NASDAQ: CNTX)
 
Price: $0.3763 $0.01 3.950%
Day's High: $0.37770000100135803 Week Perf: 3.38 %
Day's Low: $ 0.35 30 Day Perf: -22.25 %
Volume (M): 1,092,614 52 Wk High: $ 3.62
Volume (M$): $ 0 52 Wk Avg: $1.53
Open: $0.36 52 Wk Low: $0.35



 Market Capitalization (Millions $) 36
 Shares Outstanding (Millions) 95
 Employees 15
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -35
 Capital Exp. (TTM) (Millions $) 0

Business Description


Context Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative cancer treatments. The company focuses on discovering and developing drugs that target the estrogen receptor (ER) pathway in breast and other hormone-driven cancers. Their research aims to address unmet medical needs and improve patient outcomes in the field of oncology. Context Therapeutics Inc utilizes a multidisciplinary approach to drug discovery, combining cutting-edge science, computational biology, and precision medicine to identify and advance novel therapies.


   Company Address: 2001 Market Street, Philadelphia, 19103 PA
   Company Phone Number: 225-7416   Stock Exchange / Ticker: NASDAQ CNTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACRV        0.48% 
CYPH        44.11% 
DARE   -6.31%    
PMVP        10.74% 
PTPI        37.5% 
RLYB   -1.07%    
• View Complete Report
   



Shares

Context Therapeutics Expands Talent Pool with Inducement Grants Amidst Strategic Investments

Published Mon, May 12 2025 8:38 PM UTC

In a notable move to bolster its workforce, Context Therapeutics Inc. a clinical-stage biopharmaceutical company specializing in T-cell engaging bispecific antibodies for solid tumors, has announced the granting of nonqualified stock option awards. This decision was made pursuant to Nasdaq Listing Rule 5635(c)(4) and aims to incentivize new talent within the organization.On ...
Management Changes

Context Therapeutics: Bridging Challenges with Innovation in the Fight Against Cancer,

Published Mon, Jan 13 2025 12:30 PM UTC

The Evolution of Cancer Treatment: Context Therapeutics Enters a New Era with Strategic Leadership and Innovative TherapiesIn an era where the quest for effective cancer treatments is both urgent and dynamic, Context Therapeutics Inc. is making significant strides toward becoming a key player in the biopharmaceutical landscape. Recent leadership appointments and upcoming pr...
Product Service News

Advancing Cancer Treatment Context Therapeutics to Showcase CTIM-76 at SITC 2024

Published Wed, Oct 16 2024 11:30 AM UTC

: Context Therapeutics Inc. a biopharmaceutical company focused on developing innovative therapies for solid tumors, has announced the presentation of a poster highlighting its clinical asset, CTIM-76. This bispecific antibody targeting Claudin 6 and CD3 will be featured at the Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting, which will occur from November ...
Contract

BioAtla and Context Therapeutics Forge Exclusive License Agreement to Advance BA3362, a Pioneering Nectin-4 x C...

Published Mon, Sep 23 2024 11:31 AM UTC

Context to obtain exclusive development and commercialization rights to BA3362

In a significant move within the biopharmaceutical industry, BioAtla, a global clinical-stage biotechnology company, and Context Therapeutics, a biopharmaceutical company focused on novel treatments for cancer, have announced an exclusive worldwide license agreement for the deve...
Clinical Study

Innovative Therapeutics and Leadership Appointments Propel Context Therapeutics Forward in Oncology Resea...

Published Thu, Aug 1 2024 11:30 AM UTC

Context Therapeutics Inc., a pioneering company in the development of novel cancer therapies, has made a significant formal announcement regarding its leadership and clinical strategy. The recent appointments of Dr. Claudio Dansky Ullmann as Chief Medical Officer (CMO) and Ms. Karen Andreas as Vice President (VP) of Clinical Operations mark a pivotal step for the company’s...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.94
PEG (TTM) -

Financial Strength Current
Quick Ratio 5.45
Working Capital Ratio 5.84
Leverage Ratio (MRQ) 0.21
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.48 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.45 $
Book Value 0.4 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,488,364
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.